DermTech, Inc. (DMTK)

0.6440 +0.0530 (+8.97%) At close: 04:00PM EDT

DermTech, Inc.

12340 El Camino Real
San Diego, CA 92130
United States
858 450 4222
https://www.dermtech.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 206

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Kevin Sun M.B.A.	CFO, Treasurer & Secretary	461.92k	N/A	1978
Mr. Ray Akhavan Esq., J.D.	General Counsel	413.06k	N/A	1969
Mr. Bret Christensen	President, CEO & Director	N/A	N/A	1971
Mr. William W. Zondler	Chief Information Officer	N/A	N/A	N/A
Mr. Steve E. Kunszabo	Senior Director of Investor Relations	N/A	N/A	N/A
Ms. Jennifer Eilemberg	Chief Compliance Officer	N/A	N/A	N/A
Dr. Burkhard Jansen M.D.	Chief Medical Affairs Officer	419.8k	N/A	1966
Dr. Loren Clarke M.D.	Chief Medical Officer	N/A	N/A	N/A
Dr. Steven Stone Ph.D.	Senior Vice President of Research & Development	N/A	N/A	N/A
Mr. Mark Aguillard	Chief Commercial Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.

Corporate governance

DermTech, Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 7; Board: 5; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.